The Long Non-coding RNA HIF1A-AS2 Facilitates the Maintenance of Mesenchymal Glioblastoma Stem-like Cells in Hypoxic Niches  by Mineo, Marco et al.
ArticleThe Long Non-coding RNA HIF1A-AS2 Facilitates the
Maintenance of Mesenchymal Glioblastoma Stem-
like Cells in Hypoxic NichesGraphical AbstractHighlightsd lncRNA signatures reveal tissue and cellular heterogeneity in
defined GBM subtypes
d HIF1A-AS2 targets pathways that drive the adaptation to the
hypoxic niche in GBM
d HIF1A-AS2 is a mesenchymal GSC-specific lncRNA that
promotes tumorigenicityMineo et al., 2016, Cell Reports 15, 2500–2509
June 14, 2016 ª 2016 The Author(s)
http://dx.doi.org/10.1016/j.celrep.2016.05.018Authors
Marco Mineo, Franz Ricklefs,
Arun K. Rooj, ..., E. Antonio Chiocca,
Jakub Godlewski, Agnieszka Bronisz
Correspondence
eachiocca@partners.org (E.A.C.),
jgodlewski@partners.org (J.G.),
abronisz@partners.org (A.B.)
In Brief
Mineo et al. show that lncRNA HIF1A-AS2
is selectively upregulated in
mesenchymal glioblastoma stem-like
cells in response to low oxygen. Cellular
and molecular rearrangements driven by
HIF1A-AS2 and proteins from direct
interactome indicate that this lncRNA
acts in a tumor anatomic site-dependent
fashion to control adaptation to hypoxic
stress.
Cell Reports
ArticleThe Long Non-coding RNA HIF1A-AS2 Facilitates
the Maintenance of Mesenchymal Glioblastoma
Stem-like Cells in Hypoxic Niches
Marco Mineo,1 Franz Ricklefs,1,2 Arun K. Rooj,1 Shawn M. Lyons,3 Pavel Ivanov,3 Khairul I. Ansari,1,5 Ichiro Nakano,4
E. Antonio Chiocca,1,* Jakub Godlewski,1,* and Agnieszka Bronisz1,*
1Harvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School,
Boston, MA 02115, USA
2Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany
3Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
4Department of Neurosurgery and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35243-2823, USA
5Present address: Division of Neurosurgery, City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA
*Correspondence: eachiocca@partners.org (E.A.C.), jgodlewski@partners.org (J.G.), abronisz@partners.org (A.B.)
http://dx.doi.org/10.1016/j.celrep.2016.05.018SUMMARY
Long non-coding RNAs (lncRNAs) have an undefined
role in the pathobiology of glioblastoma multiforme
(GBM). These tumors are genetically and phenotypi-
cally heterogeneous with transcriptome subtype-
specific GBM stem-like cells (GSCs) that adapt to
the brain tumormicroenvironment, including hypoxic
niches. We identified hypoxia-inducible factor 1
alpha-antisense RNA 2 (HIF1A-AS2) as a subtype-
specific hypoxia-inducible lncRNA, upregulated in
mesenchymal GSCs. Its deregulation affects GSC
growth, self-renewal, and hypoxia-dependent mo-
lecular reprogramming. Among the HIF1A-AS2 inter-
actome, IGF2BP2 and DHX9 were identified as direct
partners. This association was needed for mainte-
nance of expression of their target gene, HMGA1.
Downregulation of HIF1A-AS2 led to delayed growth
of mesenchymal GSC tumors, survival benefits, and
impaired expression of HMGA1 in vivo. Our data
demonstrate that HIF1A-AS2 contributes to GSCs’
speciation and adaptation to hypoxia within the tu-
mor microenvironment, acting directly through its
interactome and targets and indirectly bymodulating
responses to hypoxic stress depending on the sub-
type-specific genetic context.INTRODUCTION
Glioblastoma multiforme (GBM) is the most common and
aggressive primary brain tumor in adults, with a median survival
of 14.2 months (Johnson and O’Neill, 2012). One of hallmarks of
GBM is its high level of heterogeneity with cells exhibiting varying
degrees of polymorphism, both phenotypically and molecularly
(Soeda et al., 2015). A sub-population of GBM cells has been2500 Cell Reports 15, 2500–2509, June 14, 2016 ª 2016 The Author(
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renewal and undifferentiated status, and these cells are
described as GBM stem-like cells (GSCs) (Singh et al., 2004).
In fact, characterization of the GBM genome (Parsons et al.,
2008) and transcriptome (Phillips et al., 2006; Verhaak et al.,
2010) has revealed the existence of several distinct cellular
subtypes among GBM patients, known as mesenchymal (M),
proneural (P), neural (N), and classical (C). Cellular heterogeneity
also was demonstrated for pure populations of GSC in culture,
based on protein-coding gene expression (Mao et al., 2013),
and, recently, single-cell RNA sequencing revealed the co-exis-
tence of different GSC subtypes within individual tumors (Patel
et al., 2014).
The complexity of solid tumors, including GBM, and their
distinct pathophysiology rely on anatomic niches that transmit
and receive signals through cellular and acellular mediators
(Jones and Wagers, 2008). The GBM microenvironment is a
complex ecosystem composed of distinct phenotypic cell com-
ponents (Patel et al., 2014), including heterogeneous tumor cells
(both GSCs andmore differentiated progenitor cells), associated
astrocytes, infiltrating immune cells and microglia, abnormal
vasculature (Meacham and Morrison, 2013), and extensive hyp-
oxic and necrotic zones (Li et al., 2009; Mathew et al., 2014).
These components are highly reliant on one another and un-
dergo constant architectural, phenotypic, and transcriptomic
re-arrangements, depending on fluctuating microenvironmental
contexts as the disease progresses (Godlewski et al., 2015).
In recent years, unprecedented progress has been made to-
ward understanding the function of non-coding RNAs (ncRNAs),
which constitute a vast majority of the human transcriptome
(Marx, 2014). Among numerous subclasses of ncRNA, a large
category is known as long ncRNA (lncRNA). Although poorly
described, it is recognized that lncRNAs are capable of tasks
such as post-transcriptional regulation, cell-cell signaling, orga-
nization of protein complexes, and their allosteric regulation.
They are involved in physiological (development and differentia-
tion; Fatica and Bozzoni, 2014) as well as pathological pro-
cesses, such as carcinogenesis (Huarte, 2015). Several lncRNAss)
creativecommons.org/licenses/by-nc-nd/4.0/).
have been described in hypoxia-associated cancer processes,
implying a potential role in maintaining cellular homeostasis
and enabling adaptive survival during hypoxia (Chang et al.,
2016; Takahashi et al., 2014). lncRNAs are involved in numerous
brain functions (Qureshi and Mehler, 2012) and have been
increasingly implicated in the pathobiology of GBM (Pastori
et al., 2015; Vassallo et al., 2016; Zhang et al., 2013). lncRNAs
that are associated with GBM subtypes and clinical prognosis
have been identified through integrative analysis of their expres-
sion profiles and clinical outcome (Du et al., 2013). Although this
analysis predicted lncRNAs that could be potential drivers of
cancer progression, it lacked functional validation.
Elucidating the biological mechanisms whereby hypoxic tu-
mor cells can adapt and survive under severe conditions is of
significant clinical importance.While it has beenwidely accepted
that proteins and microRNAs take part in hypoxic cancer pro-
gression, it is not known if and how lncRNAs participate. Here
we report that the lncRNA HIF1A-AS2 is highly expressed in M
GSCs and in GBM, but it is largely absent in adjacent brain.
HIF1A-AS2 interacts with proteins such as insulin-like growth
factor 2 mRNA-binding protein 2 (IGF2BP2) and ATP-dependent
RNA helicase A (DHX9), enhancing the expression of several of
their targets (e.g., high mobility group AT-hook 1 [HMGA1]),
and further downstream leads to changes in endothelial PAS
domain-containing protein 1 (EPAS1, also known as HIF2A)
expression and the molecular response to hypoxic stress.
Remarkably, HIF1A-AS2 regulates the growth and self-renewal
of M GSCs, and this phenotype is reflected by gene expression
rearrangements that are associated with clinical outcome.
Finally, we demonstrate that HIF1A-AS2 is essential for tumori-
genicity of M GSC-originated intracranial xenografts and that
its expression is stimulated in vivo by hypoxic stress. These re-
sults highlight a critical role for HIF1A-AS2 in the maintenance
of M GSC function, and they suggest that this lncRNA in GBM
mediates the adaptation of GSCs to hypoxic stress.
RESULTS
lncRNA Signature Reflects Intratumoral Heterogeneity
of GBM
Recognizing molecular determinants, such as lncRNAs, that act
in GSC subtypes would allow identification of functional targets
and provide much-needed insight into the contribution of
lncRNAs to GBM pathophysiology. To analyze the expression
of cancer-related lncRNAs in GBM, we designed a platform
(Table S1; Supplemental Experimental Procedures) to detect
73 cancer-related transcripts. We used our collection of GBM
specimens to screen lncRNAs, expressed in tumor tissue and
in adjacent, matched (i.e., harvested from the same individual)
brain tissue. In parallel, we isolated GSCs from GBM specimens
and cultured them in serum-free conditions as described before
(Peruzzi et al., 2013) (Figure 1A).
The analysis of lncRNA in GBM tissue revealed a tumor-spe-
cific pattern of expression: eight lncRNAs were specifically
downregulated while seven were specifically upregulated in
tumor, when compared to adjacent tissue (Figure 1B, left). The
GSC collection was characterized using a gene signature that
assigns a GSC culture to P, M, or other subtype (Mao et al.,2013) (Figure S1A). The analysis of lncRNA expression in those
GSCs also uncovered a subtype-specific pattern of expression:
20 of 64 detectable lncRNA transcripts (Figure S1B) were signif-
icantly enriched in P GSCs and seven were upregulated in M
GSCs (Figure 1B, right). The lncRNA HIF1A-AS2 was one of
the most differentially expressed in both tissues and cells
(Figure 1C, top). In fact there was significant enrichment of
HIF1A-AS2 in each GBM compared to its matched brain tissue
(Figure 1C, bottom left), as well as in M compared to P GSCs
(Figure 1C, bottom right). To validate the platform results, we
analyzed the expression of three other lncRNAs that were ex-
pressed in GSCs, P-specific MEG3, M-specific WT1-AS, and a
non-subtype-specific MALAT1 (Figure S1C). These results
show that there were GBM-specific and GBM stem cell sub-
type-specific patterns of lncRNA expression and that HIF1A-
AS2 was one of the most tumor- and subtype-specific lncRNAs.
HIF1A-AS2 Controls Cellular Fate and Molecular
Landscape of M GSCs
Wehypothesized that HIF1A-AS2de-regulationmay have impor-
tant implications for the pathobiology of GBM. Lentiviral short
hairpin RNA (shRNA)-mediated knockdown of HIF1A-AS2
resulted in its significant depletion inMGSCs (Figure 2A) and sig-
nificant impairment of growthwith a concomitant decrease in cell
viability (Figures 2B and S2A). Moreover, HIF1A-AS2 knockdown
led to diminished neurosphere-forming capacity and reduced
neurosphere size (Figures 2C and 2D). However, targeting of
HIF1A-AS2 had little effect on growth or viability of P GSCs
(Figure S2B).
To delineate the extent of the HIF1A-AS2-dependent molecu-
lar footprint, we used the Nanostring (NS) nCounter PanCancer
Pathway Panel that detects transcripts of cancer-related genes.
We observed significant de-regulation of 47/730 transcripts (Fig-
ures 2E and S2C, top). Interestingly, the majority of upregulated
genes were not P or M, while genes downregulated by HIF1A-
AS2 knockdown were expressed in P or M GSCs. (Figure S2C,
bottom). The in silico analysis revealed marked downregulation
of pro-proliferative traits concomitant with upregulation of cell
death-related processes in HIF1A-AS2 knockdown M GSCs
(Figure S2D). This prompted us to test whether genes de-
regulated by HIF1A-AS2 were associated with GBM patient
outcome. Despite using a pre-selected (biased) list of genes,
we were able to detect significant association of genes downre-
gulated in knockdown cells with poorer outcome (Figure S2E).
The physical proximity of the HIF1A-AS2 to the hypoxia-induc-
ible factor 1 alpha (HIF1A) genomic locus prompted us to test the
effect of low oxygen tension on HIF1A-AS2 transcription. This re-
vealed that, in MGSCs, HIF1A-AS2 was not only the most signif-
icantly upregulated lncRNA despite its high basal (normoxic)
levels but also one of the very few lncRNAs whose levels were
affected by hypoxic stress in GSCs (Figure 2F, middle; Table
S2), while in P GSCs the levels of HIF1A-AS2 remained low
regardless of oxygen concentration. This result was confirmed
by qPCR analysis, showing consistent upregulation across all
tested M GSCs but not P GSCs (Figure 2F, bottom). Expectedly,
levels of HIF1A and EPAS1 mRNA remained stable upon
exposure to hypoxic stress in M GSCs (with no apparent
pattern in P GSCs), whereas the respective encoded proteinsCell Reports 15, 2500–2509, June 14, 2016 2501
Figure 1. lncRNA Signature Reflects Intra-
tumoral Heterogeneity of GBM
(A) Workflow depicts the isolation of tissue and
GSCs from GBM patients for lncRNA analysis.
(B) GBM and GSC lncRNA profile distinguishes
tumor tissue (TT) from normal tissue (matched
tissue adjacent to brain tumor, TAT) and proneural
(P, blue) from mesenchymal (M, red) GSC sub-
types. lncRNA sets that vary coherently between
tissues (left) and GSCs (right) were identified by
supervised clustering (fold > 2, p < 0.05).
(C) HIF1A-AS2 is tumor- (left) and M GSC- (right)
enriched lncRNA.Relativeexpressionofall lncRNAs
(top) and HIF1A-AS2 (bottom) is shown as Nano-
string (NS reads) or qPCR. Data are shown as
mean ± SD (*p < 0.05, **p < 0.01).were consistently induced in both subtypes of GSCs (Fig-
ure S2F). Thus, the observed unaltered proliferation and viability
in both P and M GSCs under hypoxic stress (Figure S2G) under-
line the M GSC-specific HIF1A-AS2-driven program.
This effect was not limited to the stem-like cells, as differenti-
ation-promoting conditions did not abolish HIF1A-AS2 expres-
sion or its upregulation in hypoxia (Figure S2H) and also led to
maintenance of the phenotypic effect of HIF1A-AS2 knockdown
(Figure S2I).To assess HIF1A-AS2-dependent signaling during
hypoxia, we measured the dynamics of activation of several
genes that were shown to be hypoxia dependent in GBM (Patel
et al., 2014). The activation of these genes either lagged or did
not occur inMGSCs, where HIF1A-AS2was knocked down (Fig-
ure 2G). Moreover, knockdown of HIF1A-AS2 did not alter the
induction of HIF1A upon exposure to hypoxia, while induction
of EPAS1 was significantly impaired upon HIF1A-AS2 knock-2502 Cell Reports 15, 2500–2509, June 14, 2016down (Figure 2H). The hypoxic stress
caused swift and robust upregulation of
HIF1A-AS2 in M GSCs, and a similar but
weaker effect was observed in knock-
down cells, suggesting that hypoxia-
dependent induction of the endogenous
transcript overcame the shRNA effects
(Figure S2J). Similar to previous findings,
HIF1A-AS2 in M GSCs was predomi-
nantly nuclear and this distribution was
not affected by hypoxic stress (Fig-
ure S2K). Knockdown of HIF1A-AS2
resulted in an altered M GSCs pheno-
type concomitant with hypoxia-depen-
dent molecular rearrangements and
de-regulation of genes associated with
worse patient outcome, underlining the
clinical relevance of this lncRNA in GBM.
HIF1A-AS2 Drives Tumor
Progression in a Hypoxic
Environment
GBM patients with the aggressive and
predominantlyM subtype exhibit a partic-
ularly high degree of tumor necrosis (Ver-haak et al., 2010), and, conversely, highly necrotic tumors are
significantly enriched for the M transcriptional gene signature
(Cooper et al., 2012). To validate the impact of HIF1A-AS2
on tumorigenicity of GSCs, we implanted highly aggressive M
GSCs that expressed either control shRNA or HIF1A-AS2 shRNA
as intracranial xenografts (Figure 3A). We sacrificed one group of
mice after 10 days while the second group was observed for sur-
vival analysis. We observed strikingly smaller tumors in the
knockdown group after 10 days (Figures 3B and S3A). The sur-
vival benefits in the knockdown group were also significant,
although ultimately these mice perished (Figure 3C). We hypoth-
esized that, as tumorgrowthprogressesandhypoxia increases in
the tumor core, the effect of shRNAwas overridden by increased
HIF1A-AS2 expression driven by the hypoxic microenvironment
in vivo. This resulted in ultimate tumor progression and only
modest survival benefits. Thus, we analyzed the expression of
Figure 2. HIF1A-AS2 Controls Cellular Fate
and Molecular Landscape of M GSCs
(A) Downregulation of HIF1A-AS2 in M GSCs.
Short hairpin (sh)RNA strategy (left) and qPCR
analysis are shown (right). Data are shown as
mean ± SD (**p < 0.01).
(B) Knockdown of HIF1A-AS2 reduces M GSC
proliferation (left) and viability (right). Cell number
and percentage of dead cells are shown. Data are
shown as mean ± SD (**p < 0.01).
(C) Knockdown of HIF1A-AS2 inhibits sphere
formation. Sphere frequency using linear regres-
sion plot is shown.
(D) Knockdown of HIF1A-AS2 reduces sphere
growth. Representative microphotographs of GSC
spheroids (left) andquantification of sphere volume
(right) are shown. Data are shown as mean ± SD
(**p < 0.01). Scale bar represents50 mm.
(E) Knockdown of HIF1A-AS2 results in gene
expression rearrangement. Gene sets that vary
coherently between control and HIF1A-AS2
knockdownMGSCs (two single-cell clones1 and2
were analyzed) were identified by supervised
clustering (fold > 2, p < 0.05).
(F) Hypoxic stress upregulates HIF1A-AS2 in M
GSCs. Workflow depicts the hypoxic stress strat-
egy (top). Global expression of lncRNAs in nor-
moxic versus hypoxic conditions (middle) is shown
(dashed lines indicates 2-fold deregulation). The
qPCR validation of HIF1A-AS2 levels in M and P
GSCsuponexposure tohypoxia (bottom) isshown.
Data are shown as mean ± SD (**p < 0.01).
(G) Knockdown of HIF1A-AS2 alters the response
to hypoxia. The qPCR-based expression signa-
ture is shown.
(H) Knockdown of HIF1A-AS2 suppresses EPAS1
activation. Representative western blot analysis is
shown.HIF1A-AS2, HIF1A, and EPAS1 in vivo. As expected, the expres-
sion of both HIF1A and EPAS1 was much weaker in the HIF1A-
AS2knockdown versus control tumors (Figure 3D, left). However,
de-repression of the expression of HIF1A-AS2 in knockdown
cells occurred in a time-dependent fashion (in agreement with a
similar finding in vitro; Figure S2G), and in terminal tumors it
reached levels thatwerecomparable to those in control cells (Fig-
ure 3D, right). These findings implied that HIF1A-AS2 knockdown
tumors delayed their initiation phase (resulting in overall survival
benefits), albeit only transiently due to an ultimate increase of
hypoxic stress that de-repressed HIF1A-AS2 expression.
HIF1A-AS2 Interactome Targets Belong Predominantly
to a Class of RNA-Processing Proteins
To identify the HIF1A-AS2 interactome in MGSCs, we utilized an
in vitro transcription assay coupledwith transcript biotinylation to
allow pull-down of putative targets, followed by mass spectrom-
etry (MS) with additional controls of either no RNA probe or other
lncRNA (Figure 4A).We identified anumber of putative interactingCell Repartners (Table S3), with post-transcrip-
tional regulation of gene expression and
mRNA stabilization being the most pre-dominant biological processes (Figure S4A). To validate MS
results, we performed western blot analysis on RNA pull-down
material (Figure 4B, left). Identification of direct binding partners
of HIF1A-AS2 was achieved by UV-mediated cross-linking, fol-
lowedbyRNApull-down inhigh-stringencyconditions (Figure4B,
right). We identified two proteins, DHX9 and IGF2BP2, that
directly interact with HIF1A-AS2 (Figure 4B, right), but not with
another lncRNA, MEG3 (Figure 4B, bottom). The specificity of
the HIF1A-AS2-DHX9/IGF2BP2 interactions was additionally
validated by protein-RNA immunoprecipitation assays using a
panel of lncRNAs (P specific: DLEU2 and MEG3; M specific:
WT1AS, NEAT1, PRNCR1, GAS5, andRMRP; andGBMspecific:
MALAT1). This showed that onlyHIF1A-AS2physically interacted
with these two proteins and that DLEU2, MALAT1, and WT1AS
were found to interact only with IGF2BP2, althoughwith lower af-
finity (Figure S4B). Interestingly, DHX9 and IGF2BP2 have been
shown to interact with each other (Chatel-Chaix et al., 2013).
To select potential downstream effectors of HIF1A-AS2, we
first determined whether IGF2BP2 targets (Janiszewska et al.,ports 15, 2500–2509, June 14, 2016 2503
Figure 3. HIF1A-AS2 Drives Tumor Progression in a Hypoxic
Environment
(A) Workflow depicts the in vivo experimental design.
(B) HIF1A-AS2 knockdown reduces tumor volume of M GSC-originated
intracranial xenografts. Quantification of tumor volume and representative
DAPI staining of brain sections 10 days post-implantation are shown. Data are
shown as mean ± SD (**p < 0.01).
(C) HIF1A-AS2 knockdown in M GSC-originated tumors is associated with
prolonged survival. Kaplan-Meier curves are shown (n = 5; p = 0.0023).
(D) Tumor microenvironment effect on HIF1A and EPAS1 expression depends
on HIF1A-AS2 status. Representative western blot (left) and qPCR (right)
analyses are shown. Expression is relative to control M GSCs. Data are shown
as mean ± SD (**p < 0.01).2012) were subtype specific. Given that IGF2BP2 is a protein
abundantly expressed in both GSC subtypes, it was not surpris-
ing that its target genes were not P or M. Interestingly P GSC-up-
regulated targets of IGF2BP2 were not subtype specific, in
contrast to M GSC genes that overlapped with M signature
transcripts (Figure S4C). Among IGF2BP2 target genes, 49
correlated with M GSC-specific expression (Figure S4D, left).
Moreover, among IGF2BP2 target genes, there were two genes2504 Cell Reports 15, 2500–2509, June 14, 2016(HMGA1 and FOS-like antigen 1 [FOSL1]) that were downregu-
lated in both DHX9 knockdown (Figure S4D, right) (Lee et al.,
2014) and HIF1A-AS2 knockdown cells (Figure S4D). All nine
genes that were targets of IGF2BP2 and HIF1A-AS2 were
more abundant in M GSCs (Figure S4E, left). Their downregula-
tion by HIF1A-AS2 knockdown was validated by qPCR (Fig-
ure S4E, right).
Next we tested whether binding of HIF1A-AS2 to its protein
partners led to functional consequences for their downstream
RNA targets (Figure 4C). As expected, there was an interaction
between HIF1A-AS2 and DHX9/IGF2BP2 in M GSCs, but not in
P GSCs (Figure 4C, left). In addition, we found that in M GSCs
there was strong binding between IGF2BP2 and HMGA1, as ex-
pected (Janiszewska et al., 2012), and between DHX9 and
HMGA1, which has not been previously shown (Figure 4C, mid-
dle). Conversely, knockdown of HIF1A-AS2 resulted in signifi-
cantly diminished interactions between RNA-binding proteins
and their mRNA targets (Figure 4C, right). Importantly, knock-
down of HIF1A-AS2 did not alter levels of either mRNA or protein
of its interacting partners, whereas it significantly suppressed
expression of HMGA1 (Figures 4D and S4F). Although the pro-
tein levels of DHX9 and IGF2BP2 did not show a significant
difference between P and M GSCs, HMGA1 was strongly en-
riched in M GSCs (Figure S4G).
Finally, we analyzed the expression of HMGA1 in tumors
formed by HIF1A-AS2 knockdown cells, and we found that
its mRNA and protein levels were significantly elevated in the
course of tumor progression (Figure 4E), corresponding with up-
regulation of HIF1A-AS2 (Figure 3D). Therefore, we conclude
that direct interaction of HIF1A-AS2 with DHX9 and IGF2BP2
mRNA-binding complexes drives expression of their down-
stream mRNA targets with pro-oncogenic functions, such as
HMGA1, thus explaining the lncRNA-driven tumorigenic pheno-
type. As only a certain sub-population of tumor cells expresses
HIF1A-AS2 and activates it during hypoxia, we attempted to
link the transcriptome profiles of GSC subtypes, HIF1A-AS2
knockdown, and hypoxia to the intratumoral architecture
defined by predominant characteristic phenotypes of tumors
(infiltration, proliferation, and necrotic zones). As expected, the
hypoxic signature was found primarily in necrotic areas,
which significantly overlapped with the M signature, but not
with the P signature, which was detected mainly in infiltration
and proliferation zones. Interestingly, genes downregulated in
HIF1A-AS2 knockdown cells were detected predominantly in
the necrotic zone (Figure 4F; Table S4). These data implicate
HIF1A-AS2 as an lncRNA contributing to GSCs’ speciation
and adaptation to dynamic oxygen fluctuations in the tumor
microenvironment.
DISCUSSION
GSCs are highly tumorigenic and resistant to conventional radio-
and chemotherapy; therefore, they constitute the primary target
for the development of anti-GBM therapies (Lathia et al., 2015;
Sørensen et al., 2015). To date, analyses of molecular diversity
have focused mostly on protein-coding genes (Patel et al.,
2014), but the engagement and contribution of ncRNAs remain
insufficiently characterized.
Figure 4. HIF1A-AS2 Interactome Partners Belong to the Class of RNA-Processing Proteins
(A) Workflow depicting approach to identify HIF1A-AS2 interactome in MGSCs by pull-down of biotinylated transcript followed bymass spectroscopy (MS) (top).
Coomassie Blue staining of biotinylated HIF1A-AS2-associated proteins is shown (bottom, *DHX9 and **IGF2BP2 band). Binding to other RNA (MEG3) serves as
a control of binding specificity.
(B) DHX9 and IGF2BP2 are direct binding partners of HIF1A-AS2. Western blot analysis of a set of proteins identified byMS (left) and UV-crosslinked pull-down of
biotinylated HIF1A-AS2 and control RNA (MEG3) are shown (right and bottom).
(C) Binding between HIF1A-AS2 and its interacting partners affects expression of their downstream target HMGA1. Workflow depicts the RNA immunopre-
cipitation (RIP) strategy (left). Analysis of UV-crosslinked a-DHX9 RIP (top) and a-IGF2BP2 RIP (bottom) and the qPCR in P and MGSCs on HIF1A-AS2 (left) and
on HMGA1 (middle) and in control and HIF1A-AS2 knockdown M GSCs (right) are shown. Data are shown as mean ± SD (**p < 0.01).
(D) Knockdown of HIF1A-AS2 inMGSCs reduces levels of HMGA1 protein. The qPCR (left) andwestern blotting analysis (right) of selected genes inMGSCs upon
HIF1A-AS2 knockdown are shown. Expression is relative to control M GSCs. Data are shown as mean ± SD (**p < 0.01).
(E) HIF1A-AS2 knockdown-dependent suppression of HMGA1 in M GSCs is maintained at the early stage of tumor progression in vivo. The qPCR (left) and
western blot (right) analyses of HMGA1 10 days post-implantation in HIF1A-AS2 knockdownMGSCs in vivo are shown. Expression is relative to control M GSCs.
Data are shown as mean ± SD (**p < 0.01).
(F) Expression of M- or P-specific, hypoxia-dependent and HIF1A-AS2-dependent genes is prevalent in the necrotic niche of GBM. Ivy GAP database-based
expression signature in different areas of GBM for top 30 genes is shown.
(G) A proposed HIF1A-AS2-dependent signaling in a normoxic and hypoxic microenvironment of GBM is shown.Although thousands of lncRNAs have been discovered to
date, very little is known about their mode of action and possible
role in the regulation of cancer-related processes. The positive
correlation of bidirectional sense/antisense transcription is in
accord with numerous studies showing that antisense RNAs
can regulate their neighboring genes in a cis mode (Kunejet al., 2014). Here we have shown that, although HIF1A-AS2
expression responds to hypoxic stress, it had no effect on the
expression of its neighboring gene in sense orientation (HIF1A).
In fact, the HIF1A locus is ubiquitously transcribed and its protein
levels are regulated by rapid degradation under normoxic condi-
tions (Semenza, 2013; Wang et al., 1995). This highly conservedCell Reports 15, 2500–2509, June 14, 2016 2505
mechanism is unlikely to be controlled by a cell-type-specific
(Thrash-Bingham and Tartof, 1999) and not-conserved (even in
mammals) antisense transcript.
One of the prominent modes of action for lncRNAs is to
interact with other cellular factors, including proteins, DNA,
and other RNA molecules (Minajigi et al., 2015; Ulitsky and Bar-
tel, 2013). The HIF1A-AS2 protein interactome at first indicated a
multifunctional role for this lncRNA. We found that identified
direct and indirect protein targets were engaged in mRNA meta-
bolism. Interestingly, we did not find that the HIF1A-AS2 lncRNA
interacts with transcriptional machinery and protein chromatin-
remodeling complexes in GSCs, unlike what has been reported
for other lncRNAs (Flynn and Chang, 2012). It remains to be
investigated whether a direct interaction of HIF1A-AS2 with
DNA or pairing with other RNA molecules can occur. IGF2BP2,
the direct binding partner of HIF1A-AS2, has been shown to drive
a cancer stem cell phenotype in GBM by binding and stabilizing
mRNA (including HMGA1) that is enhanced by hypoxic condi-
tions (Janiszewska et al., 2012), suggesting a possible mecha-
nism for GSC adaptation to low-oxygen environments. In fact,
IGF2BP2 mRNA and protein are not deregulated in the various
GBM subtypes or by hypoxia, suggesting that its function is
regulated by co-interaction with other proteins, such as DHX9.
Such interaction already has been shown to be dependent on
the presence of RNA (Chatel-Chaix et al., 2013).
Our results suggest that HIF1A-AS2 acts by interacting with
RNA-binding proteins (IGF2BP2 and DHX9) to stimulate expres-
sion of their target mRNAs, such as HMGA1, resulting in an in-
crease in protein levels. Importantly, in addition to HMGA1’s
function during development (Chiappetta et al., 1996), it is over-
expressed in virtually every cancer (Fusco and Fedele, 2007),
and its expression levels correlate with the degree of malig-
nancy. In fact, GBM patients with higher levels of HMGA1 exhibit
a significantly shorter progression-free survival time (Liu et al.,
2015). Our findings that HIF1A-AS2 (1) is significantly overex-
pressed in GBM tumors and in M GSCs, (2) promotes stem
cell-like and tumorigenic behaviors, and that (3) its expression
is associated with GBM outcome suggest that HIF1AS-AS2 is
a non-protein-coding oncogene. However, it needs to be noted
that HIF1AS-AS2 target genes are highly or even exclusively
expressed in M GSC, indicating that HIF1A-AS2 tumorigenic
function may be cell specific. It suggests that HIF1A-AS2 may
be a contextual oncogene engaged in physiological processes
(such as maintenance of homeostasis) in other tissues/organs.
Naturally occurring oxygen gradients serve as morphogenic
signals in rapidly growing embryonic tissues (Simon and Keith,
2008), but they become extreme in pathophysiological condi-
tions, such as ischemia or the rise of solid tumors. Thus, chronic
exposure to severe oxygen deprivation frequently produces
necrotic zones surrounded by densely packed hypoxic tumor
cells. This stimulates the development of a tumoral architecture
with hierarchical cellular organization/speciation. In fact, our
recent study has shown that such cellular organization may be
recapitulated in vitro and in vivo (Ricklefs et al., 2016). Interest-
ingly, the gene analysis of GBM tissues harvested by laser
microdissection showed a GSC-specific signature associated
with tumor anatomic sites (http://glioblastoma.alleninstitute.
org) (Figure 4F). Several prominent reports (Bhat et al., 2013;2506 Cell Reports 15, 2500–2509, June 14, 2016Bozdag et al., 2014; Halliday et al., 2014; Joseph et al., 2015;
Nakano, 2014; Piao et al., 2013) have suggested that certain
microenvironmental (such as hypoxia) and therapy-inflicted
stressors (such as bevacizumab and irradiation) and/or pathway
instabilities (VEGF, NF-kB, and TNF) may have caused a transi-
tion between GBM subtypes. All these reports, however, pro-
vided strong indication of P-to-M transition, while the evidence
for the transition occurring in the opposite direction is still lack-
ing. The subtype-specific expression of HIF1A-AS2 that is
induced exclusively in M GSCs suggests that this lncRNA drives
adaptation of M GSCs to their anatomic hypoxic niche rather
than promotes transition shift from one subtype to the other.
The fact that although P GSC do not express HIF1A-AS2 but
respond to hypoxia and survive this stress suggests that diverse
programs of hypoxic response exist in these cells. The analysis
of genes deregulated by HIF1A-AS2 knockdown in M GSCs
has shown extensive deregulation; however, a shift toward other
subtypes was not observed. In fact, the M-specific signature
was downregulated while genes upregulated by HIF1A-AS2
knockdown did not cluster with either subtype. These data,
along with the fact that HIF1A-AS2 is not expressed in P GSCs
even upon hypoxic stress, indicate that this lncRNA does not
take part in a subtype switch, suggesting that P GSCs use a
different mechanism for such transition. Characterizing the
epigenetic states of phenotypically distinct cells and identifying
transcription factors that are sufficient to reprogram differenti-
ated cells into a tumorigenic stem-like state suggest a plastic
developmental hierarchy in GBM cell populations (Carro et al.,
2010; Suva` et al., 2014).
The recent observation that individual tumors contain a spec-
trum of GBM subtypes and hybrid cellular states (Patel et al.,
2014), which is reflected in the diverse expression of ncRNAs
(Du et al., 2013) and range of environmental influences (Godlew-
ski et al., 2015), adds further complexity to the pathobiology of
GBM. To fully reconstruct a network model that highlights the
critical machinery sufficient to fully reprogram differentiated
GBM cells, a comprehensive analysis of transcription factors
and their downstream effectors (both protein-coding RNAs and
ncRNAs) in the context of the tumor microenvironment is
needed. This study shows significant deregulation of lncRNA
expression in GBM using highly clinically relevant samples. The
clinical significance of our findings was underlined by linking
HIF1A-AS2 downstream effectors with patient survival out-
comes based on GBM subtypes. It is increasingly evident
that GBM/GSC subtypes use different signaling and transcrip-
tional networks (e.g., P GSC-specific Sox2, Olig2, Notch, and
PDGFRA and M GSC-specific WT1, c-Met, and EGFR) (Frattini
et al., 2013; Mao et al., 2013; Patel et al., 2014). Moreover,
GSC subtypes are characterized by divergent epigenetic foot-
prints, as, for example, the activity of Polycomb Repressor Com-
plexes (one of the most important lncRNA effectors) differs
significantly between the subtypes (Zheng et al., 2011). Our re-
sults clearly indicate that HIF1A-AS2 is selectively important
in M GSCs, as its downstream effectors (e.g., HMGA1 and
FOSL1) are expressed exclusively in M, but not P, GSCs,
providing plausible explanation for its subtype specificity. Impor-
tantly, HIF1A-AS2’s selective response to hypoxia in M GSCs
only, as these cells are found predominantly in hypoxic zones,
suggests that microenvironmental adaptation may be one of
important drivers of GSC speciation.
The association between necrosis and the M transcriptional
class in GBM highlights the important contribution of the tumor
microenvironment in implementation of hierarchical organization
of the tumor (Carro et al., 2010; Orr and Eberhart, 2012). Upregu-
lation of HIF1A-AS2 by hypoxia in M, but not P, GSCs suggests
that HIF1A-AS2 acting in GBM in a tumor anatomic site-depen-
dent fashion may control adaptation of a specific set of cells
to hypoxic stress. Some experimental evidence suggests that
tumor cells may cope with hypoxia by turning on the migratory
phenotype to escape from metabolically stressful events/loca-
tions (Brat et al., 2004). Here we argue that adaptation rather
than behavioral transition drives the survival and proliferation
of GBM cells in hypoxic zones (Figure 4G).
GBM is recognized as a complex ecosystem composed of
cells with distinct phenotypes, genotypes, and epigenetic land-
scapes. It becomes increasingly clear that the resistance to
adverse environmental conditions, such as hypoxia, contributes
to the tumor progression and reduced efficacy of anticancer
therapies. The mechanisms by which tumor cells respond and
adapt to hypoxic stress are crucial in the pathobiology of solid
tumors such as GBM. Based on our data, we propose a model
depicting an important role for HIF1A-AS2 in the regulation of
hypoxic adaptation in tumor cells in a tumor anatomic site-
dependent context, which can have important clinical implica-
tions and serve as a proof of concept for the development of
personalized GBM therapy (Reardon et al., 2015).
EXPERIMENTAL PROCEDURES
Human Specimens
Tumor and tumor-adjacent tissue samples were obtained as approved by the
Institutional Review Board at The Ohio State University and Harvard Medical
School (HMS). Surgery was conducted by E.A.C. or I.N. Patient samples
were processed for extraction of total RNA or establishment of patient-derived
neurospheres.
Cell Culture
Primary human GSCs (G2, G6, G33, G34, G35, G44, G62, G88, G146, G157,
and G91) were isolated by dissociation of gross tumor samples. The unique
identity of cultured patient-derived cells was confirmed by short tandem re-
peats analysis (Kim et al., 2016). Cells were cultured as neurospheres in
stem cell-enriched condition using Neurobasal (Gibco) supplemented with
1%Glutamine (Gibco), 2%B27 (Gibco), and 20 ng/ml epidermal growth factor
(EGF) and fibroblast growth factor (FGF)-2 (PeproTech) or in differentiation-
promoting condition using DMEM (Gibco) supplemented with 10% fetal
bovine serum (FBS, Sigma-Aldrich). For the differentiation effect, cells cultured
in stem cell-enriching conditions were transferred to differentiation-promoting
conditions. Unless otherwise specified, hypoxia experiments were performed
at 1% O2 for 24 hr. G88, G33, G816, and G44 cell lines were infected with len-
tiviral psi-LVRU6GP shCTR001 vector or psi-LVRU6GP sh217J6/J8 vectors
(GeneCopoeia).
NS Assay
NS nCounter custom-made lncRNA assay and nCounter PanCancer Path-
ways assay were performed according to the manufacturer’s instructions
(NanoString Technologies) and as previously described (Peruzzi et al., 2013).
Immunoblot Analysis and Antibodies
Immunoblotting was performed as previously described (Mineo et al., 2012).
The following antibodies were used: anti-HIF-1A (610958, BD Biosciences);anti-EPAS1 and anti-HMGA1 (7096 and 7777, respectively, Cell Signaling
Technology); anti-DHX9 and anti-IGF2BP2 (A300-855A and A303-316A,
respectively, Bethyl Laboratories); anti-NCL, anti-hnRNPA1, anti-G3BP1,
anti-HuR (ELAVL1), and anti-Fus/TLS (sc9893, sc10030, sc365338, sc5261,
and sc25540, respectively, Santa Cruz Biotechnology); and anti-Caprin1
(15112-1AP, Protein Tech Group).
RNA Pull-Down Assay
Full-length HIF1A-AS2 was cloned into pCI-neo vector (Promega). Biotin-
labeled HIF1A-AS2 was transcribed in vitro with Biotin RNA-labeling mix
(Roche) and T7 polymerase (Roche) and purified using PureLink RNA Mini
kit (Ambion). RNA was heated at 65C for 5 min and then cooled slowly for
20 min to allow secondary structure formation. GSCs were lysed in lysis buffer
(50 mM Tris, 100 mMNaCl, 1% Triton, 1 mM EDTA, 1 mM EGTA, 50 mM beta-
glycerophosphate, 1 mM DTT, 1 mM PMSF, and protease inhibitor cocktail).
For pull-down assay, 3 mg biotin-labeled HIF1A-AS2 RNAwas mixed with total
cell lysate (500 mg protein) and incubated at room temperature (RT) for 2 hr in
the presence of RNasin (100 U/ml, Promega). Washed streptavidin beads
(40 ml, Invitrogen) were added to the binding reaction and further incubated
for 1 hr at RT. Beads were washed five times in lysis buffer and bound proteins
were analyzed by MS as previously described (Bronisz et al., 2014). For UV-
crosslink RNA pull-down assays, the binding reaction was UV irradiated at
400 mJ/cm2 and then incubated with streptavidin beads at RT. After incuba-
tion, beads were washed three times with high-stringency wash buffer, three
times in high-salt wash buffer, three times in low-salt wash buffer, three times
in PXL buffer (Moore et al., 2014), and three times in lysis buffer. RNA was then
digested using RNaseA and bound proteins were analyzed by immunoblotting.
UV-Crosslink RNA Immunoprecipitation
GSCs were UV irradiated at 400 mJ/cm2 and lysed in modified radio-immuno-
precipitation assay (RIPA) buffer (50 mM Tris, 150 mM NaCl, 4 mM EDTA, 1%
NP-40, 0.1% Na-deoxycholate, 0.5 mM DTT, 100 U/ml RNasin, protease, and
phosphatase inhibitors [Roche]). Cell lysates were precleared with Protein A/G
Plus Agarose beads (Pierce) for 1 hr at 4C and incubated with primary anti-
bodies (either IGF2BP2 or DHX9) or rabbit IgG control (Santa Cruz Biotech-
nology) overnight at 4C. Protein/RNA complexes were precipitated with
Protein A/G Plus Agarose beads, washed three times with modified RIPA
buffer, washed three times with high-salt buffer (1 M NaCl modified RIPA
buffer), and then washed three times with modified RIPA buffer. Samples
were then treated with Proteinase K (Invitrogen) and RNA was extracted using
Trizol. The qPCR was performed as described above.
In Vivo Studies
Female athymic nude mice were purchased from Envigo. For all studies mice
were housed at HMS animal facility in accordance with all NIH regulations. For
intracranial tumor injection, cells were analyzed for viability using the Muse
Count & Viability Reagent on the Muse Cell Analyzer (Millipore), following
the manufacturer’s instructions to normalize number of viable cells prior
to the transplantation of 5,000 viable GSCs, transduced with either control
or HIF1A-AS2 shRNA vector and stereotactically injected (2 mm right lateral,
0.5 mm frontal to the bregma, and 4 mm deep) into the brains of 6- to
8-week-old mice. Animals were sacrificed as per protocol and brain tissue
was processed as described (Bronisz et al., 2014). Brain sections were imaged
using a confocal microscope (Zeiss LSM710).
Data and Statistical Analysis
Functional bioinformatic analyses were performed using David Functional
Annotation tool (https://david.ncifcrf.gov) and STRING v10 protein-protein
interaction networks software (Szklarczyk et al., 2015). Experimental and clin-
ical data were analyzed using the GBM-BioDP (http://gbm-biodp.nci.nih.gov)
as described (Celiku et al., 2014). Clinical data were downloaded from The
Cancer Genome Atlas (TCGA) data portal (https://tcga-data.nci.nih.gov/) as
described in TCGA research (Network, 2013). Gene expression data included
data from three platforms as follows: HT_HG-U133A (488 patient samples 3
12,042 features), HuEx-1_0-st-v2 (437 patient samples 3 18,631 features),
and AgilentG4502A_07_1/2 (101 + 396 patient sample 3 17,813 features).
The data from the three platforms were aggregated (Verhaak et al., 2010).Cell Reports 15, 2500–2509, June 14, 2016 2507
GSC microarray data (Mao et al., 2013) were queried for cluster analysis with
PANCancer platform data. Clinical data included partial clinical information on
564 patients. The experimental data were already pre-processed as a part of
TCGA data. The genes downregulated by HIF1A-AS2 knockdown were used
to predict patient outcome. Genes identified as a IGF2BP2 targets
(Janiszewska et al., 2012) were queried with genes that vary coherently be-
tween P and M GSCs (Mao et al., 2013). Gene expression in the various
anatomical regions of glioblastoma was analyzed using the Ivy Glioblastoma
Atlas Project (http://glioblastoma.alleninstitute.org/). Data are expressed as
mean ± SD. Statistical analyses were performed using the unpaired two-tailed
Student’s t test from GraphPad Prism software. Differences were considered
statistically significant at p < 0.05.SUPPLEMENTAL INFORMATION
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